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Acute myeloid leukemia (AML) is an aggressive hemato-
logical malignancy characterized by a proliferation of 
primitive myeloid cells or ‘blasts’ in the blood. Although 
highly variable, most patients with AML will achieve a 
remission but later relapse and die from the disease. It is 
an extremely heterogeneous disease at the morphological, 
molecular and clinical levels with many distinct sub-
groups. Due to this heterogeneity, classiﬁ  cation is critical 
to provide prognostic data informing risk-adapted 
therapeutic strategies, which have improved outcome 
dramatically in some subtypes of AML [1].
To date, cytogenetic abnormalities have provided most 
prognostic information, although up to 50% of patients 
have a normal karyotype [2]. In addition, over the past 
decade the detection of speciﬁ   c molecular mutations, 
including mutations in the NPM1 and FLT-3 genes, have 
provided additional prognostic information to predict 
relapse and overall survival. Global gene expression 
proﬁ  les of bulk leukemia cells have provided further data 
to improve classiﬁ  cation and prognosis [3,4], and have 
identiﬁ   ed overexpression of speciﬁ   c genes, such as 
BAALC and ERG, to be associated with poor survival. 
Th  ese studies have aided our understanding of the 
biology of AML as a disease characterized by transcrip-
tional dysregulation [5].
Our understanding of the organization of malignancy 
and the basis of therapeutic failure have recently been 
informed by the demonstration that certain malignancies 
are arranged in hierarchies and have a cancer stem or 
initiating cell at their apices, which propagates and 
maintains the tumor [6]. Th   e cancer stem cell hypothesis 
is controversial in some solid organ malignancies but is 
well accepted in leukemias, and AML was the ﬁ  rst 
malignancy in which a cancer stem cell was demonstrated 
[7,8]. Th  e malignant hierarchy in AML is similar to 
normal hematopoietic ontogeny, with leukemia stem cells 
(LSCs) in most AML patients being positive for the 
surface marker CD34, as are normal hematopoietic stem 
cells, and demonstrating variable expression of the CD38 
and CD90 markers [7-10]. However, although it is 
thought that the LSC is responsible for disease relapse 
and secondary resistance, our understanding of this 
cellular compartment is poor and it is unlikely that 
signiﬁ     cant therapeutic advances towards reducing 
disease relapse will be achieved until this ignorance is 
reversed. Speciﬁ  cally, it is not yet known whether the 
gene expression patterns in bulk tumor cells are reﬂ  ective 
of the transcriptional dysregulation in their initiating or 
stem cells; this knowledge may inform our understanding 
of their biology and suggest therapeutic targets.
Th   is issue is addressed in the interesting recent paper 
from Gentles and colleagues [11]. Th  e authors compare 
gene expression proﬁ  les in LSCs and more diﬀ  erentiated 
‘leukemia progenitor cell’ subpopulations from AML 
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ontogeny (CD34+/CD38-/CD90- and CD34+/CD38+, 
respec tively).  Th   eir dataset combines their own analysis 
of seven paired samples with a published dataset of eight 
paired gene expression proﬁ  les from LSCs that have been 
functionally validated in immunodeﬁ  cient mice [12]. Th  e 
authors found 52 genes to be diﬀ  erentially  expressed, 
with the 21 genes down-regulated in the LSC fraction 
functionally enriched for genes involved in cell cycle, 
proliferation and diﬀ   erentiation, in keeping with the 
quiescent, diﬀ   erentiation-blocked phenotype predicted 
for LSCs. Th  e 31 up-regulated genes were subsequently 
used to generate an ‘LSC signature’, where each gene was 
given a mathematical weighting relative to its predictive 
value within the dataset. Th  e sum of these weightings 
could then be calculated for a given sample to obtain a 
single value or ‘LSC score’, and this score further corre-
lated with clinical outcome and known prognostic 
factors. To address its prognostic value in AML patients, 
the ‘LSC score’ was recalculated using the same 31 genes 
in another dataset of gene expression proﬁ  les obtained 
from bulk blasts of 163 patients with normal karyotype 
AML. Th   e authors demonstrated in this ‘test’ dataset that 
a high LSC score was associated with poorer overall 
survival, both as a continuous variable or a dichotomized 
value. Importantly, they validated these ﬁ  ndings in the 
normal karyotype patients in another three large publicly 
available datasets of gene expression proﬁ  les across more 
diverse AML cases, and demonstrated similar ﬁ  ndings in 
patients with cytogenetic abnormalities. Moreover, the 
independent prognostic value of the LSC score was 
shown by multivariate Cox regression analysis to be 
independent of known prognostic factors, including age, 
karyotype and mutation of the FLT3 or NPM1 genes.
Th  ese data are important ﬁ  ndings and directly relate 
the genes dysregulated in LSCs with the outcome in 
patient samples, thus reinforcing the belief that these 
cellular populations are crucial for the propagation of 
leukemia. It is currently not practicable to predict a 
priori prognosis in patients using global gene expression 
patterns of even bulk tumor cells, although it may be 
possible that elements of this signature could be used in 
quantitative PCR assays in the future, if the elements 
were further biologically validated and the assays 
standard  ized. Although the prognostic implications of 
this study are obvious, the biological implications are less 
so. Th  e authors speculate that those leukemias with a 
high LSC score are likely to have an increased frequency 
of LSCs within the bulk tumor. Th  is interpretation is 
reasonable and would be in keeping with two previous 
reports, one of which demonstrated that a high frequency 
of phenotypic LSCs at diagnosis of AML was predictive 
of a high minimal residual disease and poor overall 
survival [13]. Th  e other, functional study demonstrated 
that the eﬃ     ciency of disease transfer into immuno-
compro  mised mice (a function of LSC activity) was also 
predictive of the clinical outcome of the patient [14]. 
Unfortunately, no correlation of the frequency of the 
LSCs, as determined by surface phenotype, with the LSC 
score was provided, as this frequency could also provide 
a surrogate prognostic marker. In addition, this study 
may also provide indirect evidence of the target cell for 
transformation to generate LSCs in AML. Th   e LSC score 
was also derived for the same 31-transcript gene set in 
normal hematopoietic stem cells and progenitor popu-
lations. Of note, the average LSC score for phenotypic 
AML LSCs was most comparable to the multipotent 
progenitor and granulocyte monocyte progenitor popu-
la tions.  Th  ese same compartments have recently been 
demonstrated to be expanded and to contain functional 
LSCs in the majority of AML cases [10]. Finally, of the 52 
genes diﬀ  erentially expressed, only a few candidate genes 
have been previously implicated in leukemogenesis, 
including  HLF [15], SETBP1 [16] and MEF2C [17]. 
Further evaluation of the other members of the gene set 
may yet provide even more information on the biology of 
the LSC in AML.
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